CD274 and neoplasm: Several biomarkers have been studied, including PD-L1 expression, mismatch repair deficiency, and tumor-infiltrating lymphocytes (TILs); however, unfortunately, these have failed to show predictive value for treatment responses in the clinical setting [16].